Chan WY, Pires da Silva I, Long GV, Rizos H. Targeting MEK in cancer and beyond: mechanistic insights and therapeutic opportunities. Lancet 2026; 407: 1639–56—In this Therapeutics paper, in table 2, the objective response rate (95% CI) should have been 15% (11–20) for the binimetinib group in the…
We thank Kevin M Johnson and colleagues for their Correspondence regarding oral vancomycin in primary sclerosing cholangitis. We acknowledge that current evidence has not identified a clear signal of increased incidence of vancomycin-resistant enterococci among individuals with primary sclerosing…
We welcome the correction to the Seminar by Erik von Seth and colleagues,1 which clarifies that no vancomycin-resistant enterococci were found in published studies of patients with primary sclerosing cholangitis treated with oral vancomycin. The incidence reported initially in the Seminar (8·7%)…
We welcome The Lancet's Editorial for highlighting the rising cancer burden among younger people.1 However, it would benefit from distinguishing adolescent and young adult (AYA) oncology from early-onset cancer: overlapping but non-synonymous concepts.
The Lancet's Editorial on cardiometabolic disease describes a growing challenge in clinical practice: patients with obesity, type 2 diabetes, chronic kidney disease, metabolic dysfunction-associated steatotic liver disease, and cardiovascular disease often attend multiple specialist clinics and…
On its 129th rescue mission, the humanitarian vessel of the non-governmental organisation Open Arms did two operations in Italy's search and rescue zone in 15 days, bringing 101 people to safety. On both occasions, the port designated by the Italian authorities for the disembarkation of the rescued…
When Evan Hubinger, a safety scientist at Anthropic, posted on X last month that there is a greater than 10% chance that artificial intelligence (AI) could kill all humans within the next decade, he was making a prophecy of eye-catching proportions. Medicine is the discipline among all disciplines…